Cristina Gervasoni to Ritonavir
This is a "connection" page, showing publications Cristina Gervasoni has written about Ritonavir.
Connection Strength
1.477
-
Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts. Eur J Clin Pharmacol. 2021 05; 77(5):791-792.
Score: 0.297
-
Darunavir does not prevent SARS-CoV-2 infection in HIV patients. Pharmacol Res. 2020 07; 157:104826.
Score: 0.284
-
The relevance of drug-drug interactions in clinical practice: the case of concomitant boosted protease inhibitors plus alpha-1 blocker administration. Antivir Ther. 2018; 23(5):467-469.
Score: 0.243
-
Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference. J Antimicrob Chemother. 2017 06 01; 72(6):1842-1844.
Score: 0.233
-
Comment on "Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6". Clin Pharmacokinet. 2021 06; 60(6):829-831.
Score: 0.076
-
Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy. Drugs Aging. 2020 12; 37(12):925-933.
Score: 0.074
-
Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study. J Med Virol. 2021 03; 93(3):1421-1427.
Score: 0.073
-
Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose? J Antimicrob Chemother. 2020 09 01; 75(9):2704-2706.
Score: 0.073
-
How relevant are the drug-drug interactions between antiretroviral boosted-based regimens and calcium channel blockers in real life? J Antimicrob Chemother. 2018 08 01; 73(8):2271-2273.
Score: 0.063
-
Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF. J Acquir Immune Defic Syndr. 2018 01 01; 77(1):86-92.
Score: 0.061